Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery

Bibliography

• Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013;Apr;14(4):248-64
   PubMed Web of Science ®Google Scholar
• Van Damme P, Robberecht W. Recent advances in motor neuron disease. Curr Opin Neurol 2009;22(5):486-92
   PubMed Web of Science ®Google Scholar
• Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007;6(11):994-1003
   PubMed Web of Science ®Google Scholar
• Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002;59(7):1077-9
   PubMed Web of Science ®Google Scholar
• Johnston CA, Stanton BR, Turner MR, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol 2006;253(12):1642-3
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Jones A, Troakes C, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 2012;124(3):339-52
   PubMed Web of Science ®Google Scholar
• Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;Jan;17(1):17-23
   PubMed Web of Science ®Google Scholar
• Bento-Abreu A, Van Damme P, Van Den Bosch L, Robberecht W. The neurobiology of amyotrophic lateral sclerosis. Eur J Neurosci 2010;31(12):2247-65
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330(9):585-91
   PubMed Web of Science ®Google Scholar
• Van Damme P, Robberecht W. Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis. Curr Opin Neurol 2013;26(5):466-72
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19(12):1584-96
   PubMed Web of Science ®Google Scholar
• Saunders NR, Daneman R, Dziegielewska KM, Liddelow SA. Transporters of the blood-brain and blood-CSF interfaces in development and in the adult. Mol Aspects Med 2013;34(2-3):742-52
   PubMed Web of Science ®Google Scholar
• Mehdipour AR, Hamidi M. Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug Discov Today 2009;14(21-22):1030-6
   PubMed Web of Science ®Google Scholar
• A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). Neurology 1999;Apr;22;52(7):1427-33
   PubMed Web of Science ®Google Scholar
• Klein SM, Behrstock S, McHugh J, et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 2005;16(4):509-21
   PubMed Web of Science ®Google Scholar
• Bongioanni P, Reali C, Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004(3):CD004302
   Google Scholar
• Chio A, Mora G, La Bella V, et al. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 2011;43(2):189-95
   PubMed Web of Science ®Google Scholar
• Beauverd M, Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012;11:CD002064
   PubMedGoogle Scholar
• Bogaert E, Van Damme P, Van Den Bosch L, Robberecht W. Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle Nerve 2006;34(4):391-405
   PubMed Web of Science ®Google Scholar
• Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2007;104(7):2495-500
   PubMed Web of Science ®Google Scholar
• Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010;113(5):1188-99
   PubMed Web of Science ®Google Scholar
• Patel P, Kriz J, Gravel M, et al. Adeno-associated Virus-mediated delivery of a Recombinant single-chain antibody against misfolded Superoxide Dismutase for treatment of Amyotrophic lateral Sclerosis. Mol Ther 2014;22(3):498-510
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem 2013;82:775-97
   PubMed Web of Science ®Google Scholar
• Deng Y, Wang CC, Choy KW, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 2014;538(2):217-27
   PubMed Web of Science ®Google Scholar
• Miller TM, Smith RA, Kordasiewicz H, Kaspar BK. Gene-targeted therapies for the central nervous system. Arch Neurol 2008;65(4):447-51
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011;478(7367):123-6
   PubMed Web of Science ®Google Scholar
• Nizzardo M, Simone C, Falcone M, et al. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis. Cell Mol Life Sci 2012;69(10):1641-50
   PubMed Web of Science ®Google Scholar
• Federici T, Boulis NM. Gene therapy for amyotrophic lateral sclerosis. Neurobiol Dis 2012;48(2):236-42
   PubMed Web of Science ®Google Scholar
• Lunn JS, Sakowski SA, Hur J, Feldman EL. Stem cell technology for neurodegenerative diseases. Ann Neurol 2011;70(3):353-61
   PubMed Web of Science ®Google Scholar
• Fishman PS, Carrigan DR. Motoneuron uptake from the circulation of the binding fragment of tetanus toxin. Arch Neurol 1988;45(5):558-61
   PubMed Web of Science ®Google Scholar
• Gabathuler R. Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier. Ther Deliv 2010;1(4):571-86
   PubMedGoogle Scholar
• Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010;37(1):48-57
   PubMed Web of Science ®Google Scholar
• Couch JA, Yu YJ, Zhang Y, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med 2013;5(183):183ra57, 1-12
   Web of Science ®Google Scholar
• Pinzon-Daza ML, Campia I, Kopecka J, et al. Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. Curr Drug Metab 2013;14(6):625-40
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997;8(3):227-34
   PubMed Web of Science ®Google Scholar
• Stetkarova I, Yablon SA, Kofler M, Stokic DS. Procedure- and device-related complications of intrathecal baclofen administration for management of adult muscle hypertonia: a review. Neurorehabil Neural Repair 2010;24(7):609-19
   PubMed Web of Science ®Google Scholar
• Harbaugh RE. Intracerebroventricular cholinergic drug administration in Alzheimer's disease: preliminary results of a double-blind study. J Neural Transm Suppl 1987;24:271-7
   PubMedGoogle Scholar
• Harbaugh RE. Intracerebroventricular bethanechol chloride administration in Alzheimer's disease. Ann N Y Acad Sci 1988;531:174-9
   PubMed Web of Science ®Google Scholar
• Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(3):201-6
   PubMed Web of Science ®Google Scholar
• Kalra S, Genge A, Arnold DL. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(1):22-6
   PubMed Web of Science ®Google Scholar
• Penn RD, Kroin JS, York MM, Cedarbaum JM. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 1997;40(1):94-9; discussion 99-100
   PubMed Web of Science ®Google Scholar
• Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2(6):696-9
   PubMed Web of Science ®Google Scholar
• Nagano I, Shiote M, Murakami T, et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res 2005;27(7):768-72
   PubMed Web of Science ®Google Scholar
• Mora JS, Munsat TL, Kao KP, et al. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology 1986;36(8):1137-40
   PubMed Web of Science ®Google Scholar
• Munsat TL, Taft J, Jackson IM, et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 1992;42(5):1049-53
   PubMed Web of Science ®Google Scholar
• Smith RA, Balis FM, Ott KH, et al. Pharmacokinetics and tolerability of ventricularly administered superoxide dismutase in monkeys and preliminary clinical observations in familial ALS. J Neurol Sci 1995;129 Suppl:13-18
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Warren L, Francis JW, et al. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Neurology 1997;49(1):213-22
   PubMed Web of Science ®Google Scholar
• Prabhakar S, Marwaha N, Lal V, et al. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study. Neurol India 2012;60(5):465-9
   PubMed Web of Science ®Google Scholar
• Baek W, Kim YS, Koh SH, et al. Stem cell transplantation into the intraventricular space via an Ommaya reservoir in a patient with amyotrophic lateral sclerosis. J Neurosurg Sci 2012;56(3):261-3
   PubMed Web of Science ®Google Scholar
• Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010;67(10):1187-94
   PubMed Web of Science ®Google Scholar
• Ishigaki A, Aoki M, Nagai M, et al. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J Neuropathol Exp Neurol 2007;66(11):1037-44
   PubMed Web of Science ®Google Scholar
• Nagano I, Ilieva H, Shiote M, et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis. J Neurol Sci 2005;235(1-2):61-8
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8(1):85-92
   PubMed Web of Science ®Google Scholar
• Poesen K, Lambrechts D, Van Damme P, et al. Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. J Neurosci 2008;28(42):10451-9
   PubMed Web of Science ®Google Scholar
• Lanka V, Cudkowicz M. Therapy development for ALS: Lessons learned and path forward. Amyotroph Lateral Scler 2008;9(3):131-40
   PubMed Web of Science ®Google Scholar
• Keifer OP Jr, O'Connor DM, Boulis NM. Gene and protein therapies utilizing VEGF for ALS. Pharmacol Ther 2014;141(3):261-71
   Web of Science ®Google Scholar
• Van Den Bosch L, Storkebaum E, Vleminckx V, et al. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol Dis 2004;17(1):21-8
   PubMed Web of Science ®Google Scholar
• Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116(8):2290-6
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013;12(5):435-42
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80(2):415-28
   PubMed Web of Science ®Google Scholar
• Sareen D, O'Rourke JG, Meera P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med 2013;5(208):208ra149
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA 2013;110(47):E4530-9
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72(2):245-56
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72(2):257-68
   PubMed Web of Science ®Google Scholar
• Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012;11(1):54-65
   PubMed Web of Science ®Google Scholar
• Debray S, Race V, Crabbe V, et al. Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. Neurobiol Aging 2013;Dec;34(12):2890-e7-2890.e12
   PubMed Web of Science ®Google Scholar
• Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007;Apr;26(1):1-13
   PubMed Web of Science ®Google Scholar
• Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5(2):140-7
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011;17(12):1652-6
   PubMed Web of Science ®Google Scholar
• Kalmar B, Lu CH, Greensmith L. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: the therapeutic potential of Arimoclomol. Pharmacol Ther 2014;141(1):40-54
   PubMed Web of Science ®Google Scholar
• Li M, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288(5464):335-9
   PubMed Web of Science ®Google Scholar
• Karlsson J, Fong KS, Hansson MJ, et al. Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neurosurg 2004;101(1):128-37
   PubMed Web of Science ®Google Scholar
• Keep M, Elmer E, Fong KS, Csiszar K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res 2001;894(2):327-31
   PubMed Web of Science ®Google Scholar
• Yin HZ, Tang DT, Weiss JH. Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS. Exp Neurol 2007;207(2):177-85
   PubMed Web of Science ®Google Scholar
• Ohta Y, Kamiya T, Nagai M, et al. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res 2008;86(13):3028-37
   PubMed Web of Science ®Google Scholar
• Chiba T, Yamada M, Sasabe J, et al. Colivelin prolongs survival of an ALS model mouse. Biochem Biophys Res Commun 2006;343(3):793-8
   PubMed Web of Science ®Google Scholar
• Locatelli F, Corti S, Papadimitriou D, et al. Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice. Ann Neurol 2007;62(1):81-92
   PubMed Web of Science ®Google Scholar
• Wang H, Yang B, Qiu L, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet 2014;23(3):668-81
   PubMed Web of Science ®Google Scholar
• Kim KS, Lee HJ, An J, et al. Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model. Cell Transplant 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Canzi L, Castellaneta V, Navone S, et al. Human skeletal muscle stem cell antiinflammatory activity ameliorates clinical outcome in amyotrophic lateral sclerosis models. Mol Med 2012;18:401-11
   PubMed Web of Science ®Google Scholar
• Knippenberg S, Thau N, Dengler R, et al. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS One 2012;7(6):e36857
   PubMed Web of Science ®Google Scholar
• Bigini P, Veglianese P, Andriolo G, et al. Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration. Rejuvenation Res 2011;14(6):623-39
   PubMed Web of Science ®Google Scholar
• Kim H, Kim HY, Choi MR, et al. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci Lett 2010;468(3):190-4
   PubMed Web of Science ®Google Scholar
• Boucherie C, Schafer S, Lavand'homme P, et al. Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis. J Neurosci Res 2009;87(9):2034-46
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhou C, Teng JJ, et al. Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis. Cytotherapy 2009;11(3):299-306
   PubMed Web of Science ®Google Scholar
• Nizzardo M, Simone C, Rizzo F, et al. Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. Hum Mol Genet 2014;23(2):342-54
   PubMed Web of Science ®Google Scholar
• Hwang DH, Lee HJ, Park IH, et al. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther 2009;16(10):1234-44
   PubMed Web of Science ®Google Scholar